AR032240A1 - A COMPILITION OF PROFILACTIC AND THERAPEUTIC VACCINE THAT INCLUDE PURIFIED WRAPPING PROTEINS OF HEPATITIS C VIRUSES - Google Patents
A COMPILITION OF PROFILACTIC AND THERAPEUTIC VACCINE THAT INCLUDE PURIFIED WRAPPING PROTEINS OF HEPATITIS C VIRUSESInfo
- Publication number
- AR032240A1 AR032240A1 ARP020100104A ARP020100104A AR032240A1 AR 032240 A1 AR032240 A1 AR 032240A1 AR P020100104 A ARP020100104 A AR P020100104A AR P020100104 A ARP020100104 A AR P020100104A AR 032240 A1 AR032240 A1 AR 032240A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- proteins
- therapeutic vaccine
- compilition
- profilactic
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 229940021747 therapeutic vaccine Drugs 0.000 title abstract 2
- 241000711557 Hepacivirus Species 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 101710125507 Integrase/recombinase Proteins 0.000 abstract 2
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 abstract 2
- 238000010494 dissociation reaction Methods 0.000 abstract 2
- 230000005593 dissociations Effects 0.000 abstract 2
- 101710091045 Envelope protein Proteins 0.000 abstract 1
- 101710188315 Protein X Proteins 0.000 abstract 1
- 102100021696 Syncytin-1 Human genes 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002934 lysing effect Effects 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 229940021993 prophylactic vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composicion de vacuna profiláctica y terapéutica que comprende una cantidad efectiva de: al menos una proteína de envoltura purificada recombinante oligomérica específica o simple del HCV seleccionada de una proteína E1, una proteína E2 y partes de dichas proteínas E1 y E2; y de manera opcional un adyuvante farmacéuticamente aceptable. Dichas composiciones están caracterizadas en que al lisar las células huésped transformadas para aislar la proteína que se expresa de forma recombinante, se realiza una disociacion de enlace de bisulfuro o paso de reduccion con un agente de disociacion de enlace de bisulfuro. Además estas composiciones que comprenden dichos péptidos utiles para el pronostico y monitoreo de la efectividad clínica y/o resultado clínico del tratamiento del HCVA prophylactic and therapeutic vaccine composition comprising an effective amount of: at least one specific or simple oligomeric recombinant purified envelope protein of HCV selected from an E1 protein, an E2 protein and portions of said E1 and E2 proteins; and optionally a pharmaceutically acceptable adjuvant. Said compositions are characterized in that by lysing the transformed host cells to isolate the recombinantly expressed protein, a bisulfide bond dissociation or reduction step is performed with a bisulfide bond dissociation agent. In addition, these compositions comprising said peptides useful for the prognosis and monitoring of the clinical effectiveness and / or clinical outcome of HCV treatment
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26066901P | 2001-01-11 | 2001-01-11 | |
| US31576801P | 2001-08-30 | 2001-08-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032240A1 true AR032240A1 (en) | 2003-10-29 |
Family
ID=26948130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020100104A AR032240A1 (en) | 2001-01-11 | 2002-01-14 | A COMPILITION OF PROFILACTIC AND THERAPEUTIC VACCINE THAT INCLUDE PURIFIED WRAPPING PROTEINS OF HEPATITIS C VIRUSES |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1463753A2 (en) |
| KR (1) | KR20020089371A (en) |
| CN (1) | CN1547588A (en) |
| AR (1) | AR032240A1 (en) |
| AU (1) | AU2002238502B2 (en) |
| BR (1) | BR0203518A (en) |
| CA (1) | CA2400643A1 (en) |
| CZ (1) | CZ20032164A3 (en) |
| HU (1) | HUP0302416A2 (en) |
| IL (1) | IL151033A0 (en) |
| MX (1) | MXPA02008886A (en) |
| NO (1) | NO20024325L (en) |
| PL (1) | PL363175A1 (en) |
| RU (1) | RU2313363C2 (en) |
| TR (1) | TR200202169T1 (en) |
| WO (1) | WO2002055548A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR035867A1 (en) | 2001-04-24 | 2004-07-21 | Innogenetics Nv | A PARTICLE SIMILAR TO A HCV VIRUS FORMED BY A HCV WRAPPING PROTEIN, A METHOD FOR FORMING THE PARTICULATE, A MEDICINAL PRODUCT CONTAINING IT, A VACCINE, A DETECTION METHOD, A DIAGNOSTIC KIT, USE OF CEPAS OF HANS FOR THE EXPRESSION OF A HCV PROTEIN, E |
| EP1558283A2 (en) * | 2002-11-08 | 2005-08-03 | Innogenetics N.V. | Hcv vaccine compositions comprising e1 and ns3 peptides |
| EP1561470A1 (en) * | 2003-06-20 | 2005-08-10 | Innogenetics N.V. | HCV vaccines comprising the envelope-1 (E1) protein or the corresponding DNA and at least one antiviral agent |
| EP2267004A3 (en) * | 2003-09-22 | 2011-04-27 | Green Peptide Co., Ltd. | Peptide derived from hepatitis C virus |
| CN100365124C (en) * | 2005-10-27 | 2008-01-30 | 云南大学 | Determination and application of hepatitis C virus specific cDNA sequence |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0721505T4 (en) * | 1994-07-29 | 2006-08-14 | Innogenetics Nv | Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use |
-
2002
- 2002-01-11 TR TR2002/02169T patent/TR200202169T1/en unknown
- 2002-01-11 KR KR1020027011431A patent/KR20020089371A/en active IP Right Grant
- 2002-01-11 HU HU0302416A patent/HUP0302416A2/en unknown
- 2002-01-11 CZ CZ20032164A patent/CZ20032164A3/en unknown
- 2002-01-11 RU RU2002121632/15A patent/RU2313363C2/en not_active IP Right Cessation
- 2002-01-11 PL PL02363175A patent/PL363175A1/en unknown
- 2002-01-11 MX MXPA02008886A patent/MXPA02008886A/en active IP Right Grant
- 2002-01-11 IL IL15103302A patent/IL151033A0/en unknown
- 2002-01-11 CN CNA028006097A patent/CN1547588A/en active Pending
- 2002-01-11 WO PCT/EP2002/000219 patent/WO2002055548A2/en active IP Right Grant
- 2002-01-11 CA CA002400643A patent/CA2400643A1/en not_active Abandoned
- 2002-01-11 AU AU2002238502A patent/AU2002238502B2/en not_active Ceased
- 2002-01-11 BR BR0203518-9A patent/BR0203518A/en not_active Withdrawn
- 2002-01-11 EP EP02704649A patent/EP1463753A2/en not_active Withdrawn
- 2002-01-14 AR ARP020100104A patent/AR032240A1/en unknown
- 2002-09-10 NO NO20024325A patent/NO20024325L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL363175A1 (en) | 2004-11-15 |
| WO2002055548A3 (en) | 2004-08-05 |
| CA2400643A1 (en) | 2002-07-18 |
| TR200202169T1 (en) | 2004-06-21 |
| CZ20032164A3 (en) | 2003-10-15 |
| RU2313363C2 (en) | 2007-12-27 |
| AU2002238502B2 (en) | 2007-09-06 |
| CN1547588A (en) | 2004-11-17 |
| BR0203518A (en) | 2002-12-17 |
| WO2002055548A8 (en) | 2002-10-31 |
| EP1463753A2 (en) | 2004-10-06 |
| WO2002055548A2 (en) | 2002-07-18 |
| NO20024325L (en) | 2002-11-11 |
| AU2002238502B9 (en) | 2002-07-24 |
| HUP0302416A2 (en) | 2003-10-28 |
| NO20024325D0 (en) | 2002-09-10 |
| AU2002238502A1 (en) | 2002-07-24 |
| KR20020089371A (en) | 2002-11-29 |
| MXPA02008886A (en) | 2003-04-25 |
| RU2002121632A (en) | 2004-03-20 |
| IL151033A0 (en) | 2003-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2174957T3 (en) | PURIFIED PROTEINS OF HEPATITIS C VIRUS WRAPPING FOR DIAGNOSTIC AND THERAPEUTIC USE. | |
| NO20052136L (en) | Hepatitis C virus (HCV) vaccine. | |
| PT1090033E (en) | HCV ENVELOPE PROTEIN PARTICLES: USED FOR VACCINATION | |
| EA200701869A1 (en) | PEPTIDOMYMETIC PROTEASE INHIBITORS | |
| MXPA02011545A (en) | Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine. | |
| ATE327246T1 (en) | HEPATITIS C TRIPEPTIDE INHIBITORS | |
| WO2005116270A3 (en) | Influenza virus vaccine composition and method of use | |
| NO20044897L (en) | Hepatitis C virus inhibitors | |
| WO2006041866A3 (en) | Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes | |
| JP2003528887A5 (en) | ||
| ATE320493T1 (en) | MODIFICATION OF HEPATITIS B CORE ANTIGEN | |
| BR0312474A (en) | Adjuvant viral particle | |
| WO2002086100A3 (en) | Expression of core-glycosylated hcv envelope proteins in yeast | |
| CL2020000295A1 (en) | Factor viii (fviii) gene therapy methods | |
| HK1047892A1 (en) | Hcv vaccine compositions | |
| MXPA04005891A (en) | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use. | |
| AR032240A1 (en) | A COMPILITION OF PROFILACTIC AND THERAPEUTIC VACCINE THAT INCLUDE PURIFIED WRAPPING PROTEINS OF HEPATITIS C VIRUSES | |
| BR0206995A (en) | Hepatitis B virus treatment | |
| WO2004041853A3 (en) | Hcv vaccine compositions comprising e1 and ns3 peptides | |
| AR041515A1 (en) | DNA VACCINE AGAINST HUMAN PAPILOMA VIRUS | |
| DE60229126D1 (en) | PRE-S-PROTEIN OF HEPATITIS B-VIRUS (HBV) AS ADJUVANS AND COMPONENT OF AN HBV VACCINE | |
| RU2004104357A (en) | VACCINE COMPOSITION POTENTIATED BY COMBINATION OF DNA AND ANTIGEN | |
| ECSP003414A (en) | ACTIVE MACROCICLIC PEPTIDES AGAINST HEPATITIS C VIRUS | |
| JP2004525885A5 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |